期刊
TRENDS IN MICROBIOLOGY
卷 22, 期 8, 页码 456-463出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.tim.2014.04.002
关键词
filovirus; Ebola; Marburg; monoclonal antibodies; immunotherapy; post-exposure
资金
- Public Health Agency of Canada (PHAC)
- Canadian Institute for Health Research (CIHR) - Canadian Safety and Security Program (CSSP)
- Canadian Institute for Health Research (CIHR)
Filovirus infections cause fatal hemorrhagic fever characterized by the initial onset of general symptoms before rapid progression to severe disease; the most virulent species can cause death to susceptible hosts within 10 days after the appearance of symptoms. Before the advent of monoclonal antibody (mAb) therapy, infection of non-human primates (NHPs) with the most virulent filovirus species was fatal if interventions were not administered within minutes. A novel nucleoside analogue, BCX4430, has since been shown to also demonstrate protective efficacy with a delayed treatment start. This review summarizes and evaluates the potential of current experimental candidates for treating filovirus disease with regard to their feasibility and use in the clinic, and assesses the most promising strategies towards the future development of a pan-filovirus medical countermeasure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据